What metrics would you use to evaluate Merck's HPV vaccine Gardasil?

Introduction

Evaluating the success of Merck's HPV vaccine Gardasil requires a comprehensive approach to product success metrics. To address this challenge effectively, I'll follow a structured framework that covers core metrics, supporting indicators, and risk factors while considering all key stakeholders.

Step 1

Product Context

Gardasil is a vaccine developed by Merck to prevent Human Papillomavirus (HPV) infections, which can lead to cervical cancer and other HPV-related diseases. Key stakeholders include patients (primarily adolescents and young adults), healthcare providers, public health officials, and Merck shareholders.

The user flow typically involves a healthcare provider recommending the vaccine, the patient or guardian consenting, and then receiving a series of shots over several months. This process requires multiple touchpoints and ongoing engagement.

Gardasil fits into Merck's broader strategy of developing preventative medicines and vaccines. It competes with GlaxoSmithKline's Cervarix, though Gardasil covers more HPV strains.

In terms of product lifecycle, Gardasil is in its maturity stage, having been on the market since 2006. However, ongoing research and potential new indications could extend its lifecycle.

As a physical product, Gardasil has unique considerations:

• Distribution channels: Primarily through healthcare providers and pharmacies
• Shelf-life: Requires careful temperature control throughout the supply chain
• Sales model: Involves both direct sales to healthcare providers and negotiations with government health agencies for large-scale vaccination programs